Attached files
file | filename |
---|---|
EX-31.1 - AIM ImmunoTech Inc. | v211077_ex31-1.htm |
EX-32.2 - AIM ImmunoTech Inc. | v211077_ex32-2.htm |
EX-23.1 - AIM ImmunoTech Inc. | v211077_ex23-1.htm |
EX-31.2 - AIM ImmunoTech Inc. | v211077_ex31-2.htm |
EX-10.26 - AIM ImmunoTech Inc. | v211077_ex10-26.htm |
10-K/A - AIM ImmunoTech Inc. | v211077_10ka.htm |
Exhibit
32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the
amended and restated Annual Report of Hemispherx Biopharma, Inc. (the “Company”)
on Form 10-K/A-2 for the fiscal year ended December 31, 2009 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”),
I, William A. Carter, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of
2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
/s/ William A. Carter
|
|
William
A. Carter, M.D.
|
|
Chief
Executive Officer
|
|
February
11, 2011
|